Christine Cassiano

• 
  Accelerator gets $11.8M to speed startup funding -... - [Cached Version]
  Published on: 11/22/2004    Last Visited: 11/23/2004  

  But the typical investment in a company is likely to be $1 million to $3 million per round, with Amgen's goal of not owning more than 15 percent of a company, said Amgen spokeswoman Christine Cassiano.
  
  Amgen strategy
  
  Amgen Ventures allows parent Amgen to build a relationship with early-stage companies to help push for scientific innovations, said Cassiano.These startups may not be far enough along with their research for Amgen's licensing division to ink a deal.But the company thinks by starting a $100 million venture capital fund, it could lead to agreements down the road."We definitely think it may pave the way for future collaboration," Cassiano said.
  
  Cassiano said the venture fund is not designed to give Amgen the inside track on cornering any company's biotech research.

• 
  Amgen - Media - Press Release - [Cached Version]
  Published on: 8/2/2005    Last Visited: 11/29/2006  

  Christine Cassiano, 805-447-4587 (Media)

• 
  Amgen grows its own VC arm - [Cached Version]
  Published on: 11/12/2004    Last Visited: 11/12/2004  

  The fund has not yet made any investments but Amgen spokeswoman Christine Cassiano said the company expects investments to range from ,1 million to ,3 million per round with an ownership stake likely less than 15%.
  
  Cassiano declined to name the executive in charge of the fund but did say that it was part of the research and development group and separate from the company's licensing group, which focuses on deals with later-stage companies.

• 
  Amgen to gain foothold in region / Biotech giant to... - [Cached Version]
  Published on: 10/8/2008    Last Visited: 3/30/2004  

  Amgen spokeswoman Christine Cassiano said most of Tularik's 400 staffers will be retained.

• 
  BioWorld Today - [Cached Version]
  Published on: 3/30/2004    Last Visited: 3/30/2004  

  "The primary motivation really had to do with adding their very strong and reputable scientific team," said Christine Cassiano, senior manager of Amgen's corporate communications.
  ...
  "There was a lot of strength and momentum from that collaboration that really made the acquisition more compelling," Cassiano said.

• 
  FaxWatch Inc. News - [Cached Version]
  Published on: 11/3/2004    Last Visited: 11/4/2004  

  Amgen spokeswoman Christin Cassiano echoed that sentiment, stating, “Given the number of products we have in our pipeline, the drug would not have received the kind of attention Nuvelo could give it.â€

• 
  Mercury News | 03/30/2004 | Biotech deal worth $1.3... - [Cached Version]
  Published on: 3/30/2004    Last Visited: 3/31/2004  

  "Obviously, having a full presence in San Francisco was definitely something in our long-term strategy," said Christine Cassiano, Amgen's senior manager of corporate communications."If we were to build from the ground up, it would take a considerable long time."
  
  She added that Amgen, which has about 13,000 employees worldwide, plans to keep most of Tularik's 375 employees.While some layoffs are likely, "they would be minimal," Cassiano said.

• 
  PharmExec - AMGEN TRANSFERS GLOBAL ALFIMEPRASE RIGHTS... - [Cached Version]
  Published on: 11/3/2004    Last Visited: 11/3/2004  

  Amgen spokeswoman Christin Cassiano echoed that sentiment, stating, "Given the number of products we have in our pipeline, the drug would not have received the kind of attention Nuvelo could give it."

• 
  TheDeal.com - Amgen grows its own VC arm - [Cached Version]
  Published on: 11/12/2004    Last Visited: 11/12/2004  

  The fund has not yet made any investments but Amgen spokeswoman Christine Cassiano said the company expects investments to range from $1 million to $3 million per round with an ownership stake likely less than 15%.
  
  Cassiano declined to name the executive in charge of the fund but did say that it was part of the research and development group and separate from the company's licensing group, which focuses on deals with later-stage companies.

• 
  Treatment has demonstrated improvement in physical... - [Cached Version]
  Published on: 11/13/2005    Last Visited: 11/15/2005  

  Contact: Christine Cassiano, Amgen805-447-4587
  ...
  Christine Cassiano (media)

Page:  1 2